Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Despite progress in cancer immunotherapy, ovarian cancer (OC) prognosis continues to be disappointing. Recent studies have shed light on how not just tumour cells, but also the complex tumour microenvironment, contribute to this unfavourable outcome of OC immunotherapy. The complexities of the immune microenvironment categorize OC as a ‘cold tumour’. Nonetheless, understanding the precise mechanisms through which the microenvironment influences the effectiveness of OC immunotherapy remains an ongoing scientific endeavour. This review primarily aims to dissect the inherent characteristics and behaviours of diverse cells within the immune microenvironment, along with an exploration into its reprogramming and metabolic changes. It is expected that these insights will elucidate the operational dynamics of the immune microenvironment in OC and lay a theoretical groundwork for improving the efficacy of immunotherapy in OC management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Research has indicated that a dose as low as 0.1 – 0.3 mg/kg of nivolumab can achieve near-complete receptor occupancy [185], less than one-tenth of the clinical dose [186].”
InfluentialMao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230 · cited 1×
“Physical barriers can be posed to infiltrating DCs and other leukocytes by the fibroblastic stroma and related extracellular matrix surrounding malignancies [76, 92].”
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572
Cancer-associated adipocytes: key players in breast cancer progression
Wu, Q., Li, B., Li, Z., Li, J., Sun, S., & Sun, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0778-6 · Cited by 462 · cited 1×
“The increase in adipose mass and associated adipose tissue alterations is now recognized as a separate risk factor for cancer development [107].”
Zamarin, D., Burger, R. A., Sill, M. W., Powell, D. J., Lankes, H. A., Feldman, M. D., Zivanovic, O., Gunderson, C., Ko, E., Mathews, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02059 · Cited by 345 · cited 1×
“[174].”
Yang, G., Rosen, D. G., Zhang, Z., Bast, R. C., Mills, G. B., Colacino, J. A., Mercado-Uribe, I., & Liu, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605752103 · Cited by 341 · cited 1×
“Gro-1 could potentially be a treatment target and diagnostic bio-marker for OC, as reprogramming the stromal microenvironment through the induction of fibroblast aging by ras-stimulated Gro-1 can enhance tumorigenesis [136].”
Tissue regulatory T cells: regulatory chameleons
Muñoz-Rojas, A. R., & Mathis, D. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00519-w · Cited by 281 · cited 1×
“Tregs are characterized by their nuclear expression of the transcription factor FoxP3 and their surface expression of CD25 and CTLA-4 [39, 40].”
Cited by
Explainable artificial intelligence for multi-modal cancer analysis: from genomics to immunology
Zhang, M., & Yin, L. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105040 · Cited by 5
Computational Design of a TCR-Based Bispecific Engager Targeting Cancerous KRAS G12V Mutations
Shah, N., Sharma, G., Patel, V., Wu, M., Mummadi, A., Taneja, A., Shah, M., Le, G. B., Krishna, M., & Brah, H. (2026) · ACS Omega · doi:10.1021/acsomega.5c10229
Metadata
- Authors
- Wang, Z., Zhang, X., Fang, C., Liu, X., Liao, Q., Wu, N., & Wang, J.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2024-04-15
- Volume
- 173
- Issue
- 1
- Pages
- 14-32
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W4394813375
- Cited by
- 204
- References
- 14
- FWCI
- 66.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. https://app.cochat.ai/papers/10.1111/imm.13793
- The paper
- Wang, Z., Zhang, X., Fang, C., Liu, X., Liao, Q., Wu, N., & Wang, J. (2024). Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. Immunology. https://doi.org/10.1111/imm.13793
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.